3 new arrests in case of U.K. nurse convicted of murdering 7 infants
All three were part of the senior leadership team at the Countess of Chester Hospital in the northwest of England between 2015 and 2016, when Letby was found to have killed the babies and attempted to kill seven others.
Letby, 35, is serving 15 consecutive life sentences with no chance of parole, but there have been questions raised about the evidence used in her trial, and her lawyer has filed for a formal review of the case.
In October 2023, following Letby's conviction, the Cheshire Constabulary police force launched an investigation into potential corporate manslaughter at the hospital, focusing on the decision-making of senior bosses, "to determine whether any criminality has taken place concerning the response to the increased levels of fatalities," according to a Tuesday statement by Detective Superintendent Paul Hughes.
That investigation was widened to include the charge of gross negligence manslaughter, leading to the arrest of the three former leaders. All three have been released on bail pending further investigation, the police said.
"Both the corporate manslaughter and gross negligence manslaughter elements of the investigation are continuing and there are no set timescales for these," Hughes said.
"It is important to note that this does not impact on the convictions of Lucy Letby for multiple offenses of murder and attempted murder," he added.
The Cheshire police are also investigating deaths and non-fatal collapses of babies at the neonatal units of the Countess of Chester Hospital and the Liverpool Women's Hospital between 2012 and 2016, where Letby did her training.
Lucy Letby's controversial murder conviction
Since her conviction, there have been significant concerns voiced over the evidence used to secure Letby's conviction, with The New Yorker, The Guardian, Private Eye and other outlets reporting on possible alleged flaws in the trial proceedings.
In February, a group of experts held a news conference to dispute the medical evidence used to convict Letby.
Dr. Shoo Lee, a retired Canadian neonatologist, said the group of 14 doctors had concluded that the newborns died either of natural causes or from insufficient medical care.
"In summary then, ladies and gentlemen, we did not find murders," Lee said at the time
Letby has maintained her innocence.
Her defense attorney Mark McDonald said in April that the experts' findings had "completely demolished" the case against Letby, whom he argues was wrongly convicted. McDonald said he had submitted an application to the Criminal Cases Review Commission (CCRC), which has the power to send cases back to the Court of Appeal.
The CCRC has given no date for when a decision might be reached.
In a statement sent to CBS News on Tuesday, McDonald said that despite the news of the three new arrests, "the concerns many have raised will not go away, and we will continue to publicly discuss them."
"What is needed is a proper and full public inquiry into the failings of the neonatal and paediatric medical care unit at the Countess of Chester hospital," McDonald said, repeating his assertion that Letby was wrongfully convicted.
Jury has more questions in Sean "Diddy" Combs trial
Details on the "Alligator Alcatraz" immigration detention center
Last-minute rural health care change helped Senate pass Trump budget bill, lawmakers react
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Artificial Intelligence Reshapes Diagnostic Imaging for Early Disease Detection
Artificial intelligence gives us the ability to see what the human eye might miss—and to act before it's too late. This is not just a technological advancement; it's a shift in how we protect lives, deliver care, and ensure no patient is left behind. Healthcare visionary Hugo Raposo unveils scalable imaging solution to flag critical conditions before symptoms appear. A quiet breakthrough is unfolding in medical imaging—and it's powered not by new machines, but by new intelligence. Canadian technology strategist Hugo Raposo has developed an artificial intelligence platform that rapidly analyzes diagnostic images to detect early signs of disease, with the potential to transform patient outcomes at scale. From routine X-rays to advanced MRI and CT scans, the platform acts as an intelligent assistant —one that never tires, forgets, or overlooks the fine details. Deployed in select clinical settings across Ontario, it has already shown promise in reducing diagnostic delays and identifying at-risk patients long before symptoms surface. Automating the Invisible: A Second Set of Eyes for Every Scan Built on machine learning and advanced pattern recognition, the platform interprets clinical images in real time, surfacing subtle abnormalities that might escape even experienced eyes under pressure. It's not just about speed—it's about catching what would otherwise be missed: 'Radiologists are under immense strain,' said one Toronto-based imaging lead familiar with the rollout. 'This kind of tool doesn't just help—it protects. It extends the quality of care without increasing the workload.' About the Architect Behind the Platform Hugo Raposo is no stranger to complex healthcare challenges. With nearly three decades of experience in enterprise architecture and digital health, he served as Chief Architect for one of Canada's largest provincial healthcare transformation programs. His work bridges clinical operations, AI innovation, and scalable infrastructure—often with an emphasis on underserved or high-risk populations. He has advised executive teams, contributed to public-sector modernization, and spoken internationally on the intersection of technology and health equity. More on Raposo: Real-World Results and Clinical Potential In early deployments, Raposo's platform has helped care teams: One pilot site saw a drop in unnecessary imaging repeat requests within weeks—thanks to clearer, AI-assisted reporting. Another clinic, serving a rural population, credited the system with improving access to rapid pre-screening where radiologist review was delayed. Beyond Hospitals: Designing for Accessibility Unlike many AI health tools that remain confined to research labs or top-tier institutions, this system was designed for broad use. It operates with or without cloud access, supports mobile deployments, and integrates into existing PACS and EHR systems. 'We didn't build this for showcase hospitals,' Raposo said in an interview. 'We built it for the real world—where a delay in reading a scan can mean the difference between early treatment and emergency surgery.' The technology adheres to privacy-by-design principles, using federated learning to prevent raw image data from leaving local environments. Model updates and quality controls are handled through a rigorous oversight framework, with bias mitigation and auditability at the core. Policy Alignment and Global Relevance With the U.S. and Canada facing rising diagnostic backlogs, Raposo's work intersects with key national goals: The system's compatibility with both urban and low-resource clinical settings positions it as a candidate for broader adoption in public health and emergency response networks. What Comes Next Raposo is advancing the platform's capabilities to analyze cardiovascular scans and identify early indicators of cognitive decline. He is also developing multi-modality correlation features that link insights across radiology, pathology, and lab data—creating a comprehensive diagnostic profile driven by artificial intelligence. 'This is just the beginning,' Raposo said. 'We're not replacing clinicians. We're giving them clarity faster, and with that, the power to intervene sooner.' Media Contact Company Name: Contatto Media Agency Contact Person: Boracini, Paula Email: Send Email Country: Canada Website: Press Release Distributed by To view the original version on ABNewswire visit: Artificial Intelligence Reshapes Diagnostic Imaging for Early Disease Detection
Yahoo
4 hours ago
- Yahoo
What we know as Lucy Letby may face more murder charges
Convicted baby killer nurse Lucy Letby could face more criminal charges after murder squad detectives passed evidence of further allegations related to baby deaths and collapses at the hospitals where she worked. The number and exact nature of the potential new offences has not been made public yet and it could take weeks before a decision is made by the Crown Prosecution Service (CPS) on whether to charge Letby with more offences. A Cheshire police spokeswoman said: 'We can confirm that Cheshire Constabulary has submitted a full file of evidence to the CPS for charging advice regarding the ongoing investigation into deaths and non-fatal collapses of babies at the neonatal units of both the Countess of Chester Hospital and the Liverpool Women's Hospital as part of Operation Hummingbird.' News of the potential new charges comes after three people who were part of the senior leadership team at the hospital where Letby worked were arrested on suspicion of gross negligence manslaughter. The suspects, who occupied senior positions at the Countess of Chester Hospital (CoCH) between 2015 and 2016, were arrested on Monday. Following the lengthy trial and conviction of Letby in August 2023, the police force launched an investigation into corporate manslaughter, and later gross negligence manslaughter, at the hospital – leading to the latest arrests. Police have said investigations at the Countess of Chester are continuing and that the probe does not impact Letby's multiple murder and attempted murder convictions. Here's what we know so far. The three suspects, who occupied senior positions at the CoCH between 2015 and 2016, were arrested on 30 June on suspicion of gross negligence manslaughter. All three have since been bailed pending further inquiries, the force added. Police said corporate manslaughter and gross negligence manslaughter probes are continuing. Cheshire Constabulary said it launched its investigation into senior management at the hospital in October 2023, a few months after Letby's conviction. Its corporate manslaughter probe is focusing on "senior leadership and their decision-making to determine whether any criminality has taken place concerning the response to the increased levels of fatalities", Detective Superintendent Paul Hughes said. In March 2025 the scope of the investigation widened to also include gross negligence manslaughter – a separate offence which "focuses on the grossly negligent action or inaction of individuals", police added. Police are yet to reveal the identities of the three people who were arrested, as it is standard for authorities to only name suspects publicly once they have been formally charged. While we know that the three suspects were part of the hospital's senior leadership team, it is not clear exactly what jobs they held, or what their working relationship was with Lucy Letby. The investigation followed Letby's convictions, but it is not known whether the alleged cases of gross negligence are directly linked to the 35-year-old former nurse's actions at the CoCH. A spokeswoman for CoCH reiterated it 'would not be appropriate' for the hospital to comment 'due to the Thirlwall Inquiry and the ongoing police investigations'. According to the Crown Prosecution Service (CPS), gross negligence manslaughter is committed where the death is a result of a grossly negligent (though otherwise lawful) act or omission on the part of the defendant. Circumstances where this can occur are "almost infinitely variable", the CPS says, but here are some examples that could apply: Death following medical treatment or care; the offence can be committed by any healthcare professional, including but not exclusively doctors, nurses, pharmacists and ambulance personnel. Deaths in the workplace the offence can be committed by anyone who is connected in some way to a workplace of any nature. The context is wide ranging but can include offices, factories, ships, airports, aeroplanes, construction sites, oil rigs, farms, schools and sporting grounds. The deceased victims may be employees, contractors, sub-contractors, and members of the public visiting or passing by the workplace when a fatal incident happens. Death in custody – a death in custody is a generic term referring to deaths of those in the custody of the state. In this context the offence can be committed by police or prison officers, dedicated detention and other custody assistants, and by healthcare professionals who are responsible for the care of those detained in a custodial setting. According to the Sentencing Council, gross negligence manslaughter is triable only on indictment, and carries a sentencing range of 1 – 18 years in custody. The length of sentence for this offence is determined by a scale of culpability (category A being the highest and D being the lowest), as shown on the council's website. Repeated negligence, blatant disregard for high risk of death and motivation by financial gain are all considered for higher penalties. Read more NHS will use AI to prevent next Letby scandal (The Telegraph) Nurse loses appeal against 2008 convictions for murder of four patients in Leeds (The Guardian) Repeated failings by the nursing regulator demand a new approach (The Independent)
CNBC
5 hours ago
- CNBC
London stock market could weather its biggest blow yet if AstraZeneca exits
Pressure is piling on London's stock exchange, with reports that British pharma giant AstraZeneca may move its listing to the U.S. delivering yet another blow this week. CEO Pascal Soriot is considering moving the company's stock listing from London to the U.S., British newspaper The Times reported on Tuesday afternoon, citing anonymous sources. Soriot's frustrations with the U.K.'s regulatory environment — particularly rules around new medicine approvals and drug pricing systems — are said to be driving the move. AstraZeneca declined to comment on the Times report. The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable business listed on London's FTSE 100. AstraZeneca's market cap was £161.2 billion ($221.1 billion) as of Tuesday's closing price, according to LSEG data. AstraZeneca's potential transatlantic move would add to concerns around London's weakening status as a global financial hub. A number of companies have delisted from the London market or reconsidered plans to float shares in the city over the past year. Toni Meadows, head of investment at London's BRI Wealth Management, labeled AstraZeneca's rumored listing considerations as "disappointing" for the U.K. equity market — but he conceded that "it is not surprising" given that it would form the latest development in a wider established trend. Earlier this year, reports emerged that Chinese fast fashion giant Shein was looking to list in Hong Kong instead of London, when it goes public. Last week, news agency Reuters reported that the company was planning to file confidentially for a Hong Kong IPO. Metals investor Cobalt Holdings, meanwhile, confirmed to CNBC last month that it had scrapped plans for a London IPO, while British fintech giant Wise announced in June that it was moving its primary listing from London to New York. Kristo Kaarmann, Wise's CEO and co-founder, said in a statement at the time that the move would help raise awareness of the company in the U.S., while giving the firm better access to "the world's deepest and most liquid capital market." Companies listed in London have historically had much lower valuations than their Wall Street counterparts. Research from British investment manager Rathbones last year showed that the forward price-to-earnings ratio for U.K. stocks was 32% lower than those listed in the U.S. on a like-for-like basis. On the flipside, the Financial Times reported last week that Norwegian software giant Visma had chosen London for its upcoming debut on the public market. "Large and important companies like AstraZeneca are seeking a valuation uplift from exposure to a wider investor base and they will get that from moving to a US listing," BRI's Meadows told CNBC via email on Wednesday. "The trend to move listing, or the stream of takeovers for UK listed stocks, highlights value in the UK equity market, but it does nothing to encourage a new supply of companies listing here to support the future standing of the index in a Global context," Meadows added. Claire Trachet, founder of M&A advisory Trachet, said AstraZeneca shifting its listing to New York would represent "a memorable loss" for the London Stock Exchange. "Given the complexity of the company, this isn't simply because of liquidity or valuation advantages often cited by departing firms, rather a trifecta of underperforming capital markets, regulatory constraints, and misaligned incentives that make it harder to scale and reward innovation at home," she told CNBC by email. Trachet added that London-listed companies with a combined value in excess of $100 billion had already made the move to New York in recent years — and AstraZeneca's departure alone would more than double that figure. "The potential move makes it painfully clear to global markets that the UK is losing its edge on the needs of world-class, scale-driven companies," she said. "This isn't an isolated story — and that's the biggest issue. It's part of a broader shift, where founders and boards are increasingly looking to the US for deeper capital, stronger support, and a more ambitious investor base." Tom Bacon, a London-based partner at global law firm BCLP — which has a division dedicated to M&A and corporate finance — labeled reports of AstraZeneca's Soriot's desire to shift away from London "very worrying." "I think this should sound the alarm for the UK government that they need to do more both to support the city and our stock market together with our critical industries like life sciences and pharmaceuticals," he said. Dan Coatsworth, investment analyst at AJ Bell, on Wednesday said that AstraZeneca's reported plans appeared to be driven by business needs rather than chasing a higher valuation — but he added that moving the company's listing across the Atlantic "won't be an easy move to pull off." "Unlike many other UK market 'defectors' with a dominant US shareholder base like CRH and Flutter, AstraZeneca has a more geographically diverse pool of investors," he explained in an email. However, Coatsworth noted that AstraZeneca generates around 42% of its sales from the U.S., and already has plans to increase its operational footprint in the country. Earlier this year, CEO Soriot told CNBC AstraZeneca was "very committed to the United States," where the company has two large research and development centers. AJ Bell's Coatsworth told CNBC that AstraZeneca's CEO could also see a full U.S. stock listing as a "stepping stone to receiving better treatment Stateside." European pharmaceutical companies are facing uncertainty around their future in the American market, where U.S. President Donald Trump has threatened to impose sector-specific tariffs on drug imports. While the industry was exempted from Trump's so-called reciprocal tariffs plans when they were unveiled in April, the White House leader has since placed the sector under investigation by the U.S. Commerce Department, warned tariffs on pharma are "coming soon," and signed an executive order directing medicine manufacturers to lower the price of some drugs in line with costs paid overseas.
